Sogawa Chiharu, Shimada Katsumitsu, Nakano Keisuke
Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology, 2-1-1 Miyake, Saeki-ku, Hiroshima 731-5193, Japan.
Department of Clinical Engineering Faculty of Life Sciences, Hiroshima Institute of Technology, 2-1-1 Miyake, Saeki-ku, Hiroshima 731-5193, Japan.
Int J Mol Sci. 2025 May 1;26(9):4310. doi: 10.3390/ijms26094310.
Plasma membrane transporters are increasingly recognized as potential drug targets for oral cancer, particularly oral squamous cell carcinoma (OSCC). These transporters play crucial roles in cancer cell metabolism, drug resistance, and the tumor microenvironment, making them attractive targets for therapeutic intervention. Among the two main families of plasma membrane transporters, ATP-binding cassette (ABC) transporters have long been known to be involved in drug efflux and contribute to chemoresistance in cancer cells. On the other hand, solute carriers (SLCs) are also a family of transporters that facilitate the transport of various substrates, including nutrients and drugs, and have recently been shown to contribute to cancer chemosensitivity, metabolism, and proliferation. SLC transporters have been identified as potential cancer biomarkers and therapeutic targets, and their expression profiles suggest that they could be utilized in precision oncology approaches. We summarize previous reports on the expression and role of ABC and SLC transporters in oral cancer and discuss their potential as therapeutic targets.
质膜转运蛋白越来越被认为是口腔癌，尤其是口腔鳞状细胞癌（OSCC）的潜在药物靶点。这些转运蛋白在癌细胞代谢、耐药性和肿瘤微环境中发挥着关键作用，使其成为治疗干预的有吸引力的靶点。在质膜转运蛋白的两个主要家族中，ATP结合盒（ABC）转运蛋白长期以来一直被认为参与药物外排并导致癌细胞的化疗耐药性。另一方面，溶质载体（SLC）也是一类转运蛋白家族，它们促进包括营养物质和药物在内的各种底物的转运，最近已被证明与癌症化疗敏感性、代谢和增殖有关。SLC转运蛋白已被确定为潜在的癌症生物标志物和治疗靶点，其表达谱表明它们可用于精准肿瘤学方法。我们总结了先前关于ABC和SLC转运蛋白在口腔癌中的表达和作用的报道，并讨论了它们作为治疗靶点的潜力。
